Rate Video

SITC 2021 | Tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma

Omid Hamid • 12 Nov 2021

Melanoma Skin Cancer Antibodies Durvalumab Tebentafusp Tremelimumab

Immuno-Oncology

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the results of a Phase Ib study evaluating tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma (NCT02535078). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Clinical activity of fianlimab, an anti-LAG-3 mAb combined with cemiplimab in advanced melanoma

Omid Hamid • 21 May 2021

Safety of continued dosing of MEDI1191

Omid Hamid • 12 Mar 2021

First-in-class anti-CD96 monoclonal antibody alone or with dostarlimab for advanced tumors

Omid Hamid • 12 Nov 2021

Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors

Omid Hamid • 12 Nov 2021

Related Videos

Adjuvant nivolumab in patents with high-risk resected melanoma

Jeffrey Weber • 16 Nov 2021

Early results from ONCR-177-101: ONCR-177 alone or in combination with anti-PD-1 blockade

Jong Chul Park • 13 Nov 2021

Highlights for melanoma at SITC 2021

Diwakar Davar • 13 Nov 2021

Current status of immunotherapy for advanced melanoma

Omid Hamid • 12 Nov 2021